Aptamer of maytansine and application thereof
By developing Seq2-X, a highly specific maytansin nucleic acid aptamer, combined with biotin, fluorescent substances, nanoluminescent materials or enzyme labels, the problems of poor water solubility and poor stability of maytansin in clinical applications have been solved, and the problem of poor water solubility and stability of maytansin in clinical applications has been achieved. Improve solubility and stability, broaden treatment windows, simplify production processes and reduce costs, and enhance drug cytotoxicity and safety.
Patent Information
- Application Number
- CN202310601632.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-25
AI Technical Summary
As an anti-tumor drug, maytansin has problems such as poor water solubility, poor stability and narrow treatment window in clinical applications. The existing technology covalent coupling methods and nano-drug preparation methods are due to high production costs, cumbersome preparation processes, and large-scale production. There are no reports on its nucleic acid aptamers for limitations such as difficulties.
A maytansin nucleic acid aptamer Seq2-X with high specificity, strong affinity, low immunogenicity, batch synthesized, biocompatible and stable, was developed, and luminescent with biotin, fluorescent substances, and nanometers. The combination of materials or enzyme labels improves the solubility and stability of drugs and broadens the therapeutic window.
Achieve high affinity binding between maytansin and nucleic acid aptamers, improve the solubility and stability of the drug, reduce toxic side effects, broaden the treatment window, simplify the production process, reduce costs, and enhance the cells of the drug. Toxicity promotes the effectiveness and safety of the drug.
Smart Images

Figure CN119020365A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of molecular biology and relates to a nucleic acid aptamer and an application thereof, and specifically relates to a nucleic acid aptamer of an anti-tumor drug maytansine and an application thereof. Background Art
[0002] Maytansine is an anti-tumor drug containing a macrolide structure, which can effectively inhibit the proliferation of malignant tumors, but its toxic side effects cannot be ignored. Maytansine has problems such as poor water solubility, poor stability and narrow therapeutic window in clinical applications. In order to solve these problems, people have used antibodies or nucleic acid aptamers to construct covalent conjugates with maytansine, or maytansine has been prepared into nano drugs to solve the limitations of its clinical application. However, although these two methods have achieved obvious results, they are still limited by factors such as high production cost, cumbersome preparation process, and difficulty in large-scale production. Therefore, the clinical application of maytansine still has great challenges.
[0003] Aptamers are single-stranded oligonucleotides (single-stranded DNA or RNA) that can specifically bind to targets, obtained by screening through the systematic evolution of ligands by exponential enrichment (SELEX). Aptamers have comparable affinity and specificity to antibodies, and have more advantages than antibodies, such as small molecular weight, low immunogenicity, easy chemical synthesis, low cost, easy modification and flexible design, stable properties, and easy storage. Unlike the covalent coupling mode between aptamers and drugs, the specific binding of aptamers to targets is achieved through non-covalent interactions such as hydrogen bonds and van der Waals forces. Therefore, using aptamers as a carrier may bring new ideas and methods for drug delivery.
[0004] However, there are no reports on maytansine aptamers. Therefore, if a nucleic acid aptamer that specifically binds to maytansine can be obtained, the affinity between maytansine and its nucleic acid aptamer will hopefully solve the limitations of maytansine in clinical applications, thereby providing a new research perspective for delivering the anti-tumor drug maytansine. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the deficiencies of the prior art and provide a nucleic acid aptamer of maytansine that can bind to maytansine with high specificity and high affinity, has low immunogenicity, can be synthesized in batches, has good biocompatibility and stability, has a small molecular weight, and is easy to store; and also provides the application of the above-mentioned nucleic acid aptamer in solving the limitations of maytansine in clinical applications.
[0006] In order to solve the above technical problems, the present invention provides a nucleic acid aptamer of maytansine, wherein the nucleic acid aptamer is Seq2-X, and the DNA sequence of Seq2-X is shown in SEQ ID NO.1.
[0007] The above-mentioned nucleic acid aptamer, further, is a nucleic acid aptamer that binds biotin, digoxigenin, a fluorescent substance, a nanoluminescent material or an enzyme label to the DNA sequence of Seq2-X.
[0008] In the above-mentioned nucleic acid aptamer, further, the fluorescent substance is a FAM fluorescent group or a Cy5 fluorescent group; the nanoluminescent material is a quantum dot or an upconversion nanoparticle; and the enzyme marker is horseradish peroxidase or sucrase.
[0009] The above-mentioned nucleic acid aptamer, further, the nucleic acid aptamer is phosphorylated, methylated, aminated, thiolated or isotopized at a certain position on the nucleotide sequence of the nucleic acid aptamer Seq2-X under the premise that the overall structure of Seq2-X remains unchanged.
[0010] For the above-mentioned nucleic acid aptamer, further, the amination is to label the 5' or 3' end of the nucleic acid aptamer Seq2-X nucleotide sequence with an amino group -NH2; the thiolation is to label the 5' or 3' end of the nucleic acid aptamer Seq2-X nucleotide sequence with a thiol group -SH.
[0011] The above-mentioned nucleic acid aptamer, further, is a nucleic acid aptamer whose DNA sequence is any one of the following four sequences:
[0012] (1) having a nucleotide sequence homology of more than 60% with the nucleic acid aptamer Seq2-X;
[0013] (2) a sequence that hybridizes with the nucleotide sequence of the nucleic acid aptamer Seq2-X;
[0014] (3) an RNA sequence transcribed from the nucleotide sequence of the nucleic acid aptamer Seq2-X;
[0015] (4) It is a derivative of Seq2-X, wherein the derivative is a phosphorothioate backbone derived from the backbone of the nucleotide sequence of the nucleic acid aptamer Seq2-X, or is a corresponding locked nucleic acid or peptide nucleic acid modified from the nucleic acid aptamer.
[0016] Based on a general technical concept, the present invention also provides a use of the nucleic acid aptamer in improving the solubility of maytansine.
[0017] Based on a general technical concept, the present invention also provides an application of the nucleic acid aptamer in broadening the therapeutic window of maytansine.
[0018] Based on a general technical concept, the present invention also provides an application of the nucleic acid aptamer in improving the stability of maytansine.
[0019] Based on a general technical concept, the present invention also provides an application of the nucleic acid aptamer in a drug carrier.
[0020] Compared with the prior art, the advantages of the present invention are:
[0021] (1) The present invention provides a nucleic acid aptamer for the anti-tumor drug maytansine, which can bind to the target maytansine with high affinity and high specificity, and the equilibrium dissociation constant is in the nanomolar range.
[0022] (2) The present invention provides a nucleic acid aptamer for the anti-tumor drug maytansine. Compared with protein antibodies, nucleic acid aptamers have lower immunogenicity, can be synthesized in batches in vitro, have a small molecular weight, can be modified and replaced at different sites, and have stable chemical properties, are easy to store, and are convenient for labeling. At the same time, nucleic acid aptamers have good water solubility. After combining with the fat-soluble drug maytansine, the solubility of the drug can be improved, avoiding the toxic side effects caused by the addition of organic solvents (such as DMSO, etc.) or surfactants (such as Tween, etc.).
[0023] (3) The present invention provides a nucleic acid aptamer for an anti-tumor drug, maytansine. The specific interaction between the nucleic acid aptamer and maytansine can improve the stability of maytansine drugs, enhance the cytotoxicity of maytansine, and thus broaden its treatment window. The use of the nucleic acid aptamer of the present invention as a drug delivery carrier for maytansine can improve the limitations of the clinical application of maytansine (improve solubility, improve stability, and broaden the treatment window), which is of great significance for the design and development of maytansine drugs in clinical applications. At the same time, corresponding labeling, modification or substitution of the nucleic acid aptamer of the present invention is conducive to the tracing of maytansine in vivo, helps to reveal the mechanism of drug absorption, distribution, metabolism and excretion, and promotes the effectiveness and safety of drug treatment.
[0024] In addition to the above-described purposes, features and advantages, the present invention has other purposes, features and advantages. The present invention will be further described in detail below with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The drawings constituting a part of this application are used to provide a further understanding of the present invention. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0026] Figure 1 This is a schematic diagram of the structure obtained by performing secondary structure simulation on the nucleic acid aptamer Seq2-X sequence using the Mfold service in Experiment 1 of the present invention.
[0027] Figure 2 This is a concentration optimization diagram of the incubation of the nucleic acid aptamer FAM-Seq2-X and the quenching probe Quencher in Experiment 2 of the present invention, wherein the horizontal axis represents the quenching probe with gradually increasing concentrations, and the vertical axis represents the fluorescence intensity.
[0028] Figure 3 This is the fluorescence recovery saturation curve after incubation with different concentrations of maytansine at the optimal quenching ratio of FAM-Seq2-X and Quencher in Experiment 3 of the present invention, wherein the horizontal axis is the gradually increasing concentration of maytansine, and the vertical axis is the fluorescence intensity.
[0029] Figure 4 This is the result of investigating the specificity of the nucleic acid aptamer FAM-Seq2-X in Experiment 4 of the present invention.
[0030] Figure 5 The results of the nucleic acid aptamer Seq2-X improving the solubility of maytansine at different incubation times in Experiment 5 of the present invention.
[0031] Figure 6 These are the results of different concentrations of nucleic acid aptamer Seq2-X improving the solubility of maytansine in Experiment 6 of the present invention.
[0032] Figure 7 These are the results of an investigation into the use of the nucleic acid aptamer Seq2-X in Experiment 7 of the present invention to broaden the therapeutic window of metansine.
[0033] Figure 8 This is the investigation result of the nucleic acid aptamer Seq2-X in Experiment 8 of the present invention in improving the stability of maytansine. DETAILED DESCRIPTION
[0034] The present invention will be further described below in conjunction with the accompanying drawings and specific preferred embodiments, but the protection scope of the present invention is not limited thereby. The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with embodiments.
[0035] The materials and instruments used in the following examples are all commercially available.
[0036] Example 1
[0037] The present invention provides a maytansine aptamer, the aptamer is a aptamer Seq2-X, the nucleotide sequence of the aptamer Seq2-X is a DNA fragment shown in SEQ ID NO.1, specifically as follows:
[0038] 5'-CTCTCGGGACGACTTGTCATGTGTAGAAGGAGTGGGTTGAGATGTCGTCCC-3'.
[0039] The above-mentioned nucleic acid aptamer Seq2-X is mainly obtained by the following screening method:
[0040] (1) Synthesize the random single-stranded DNA library, primers and capture strands shown in the following sequences.
[0041] Random single-stranded DNA library:
[0042] 5'-GGAGGCTCTCGGGACGAC-N30-GTCGTCCCGATGCTGCAATCGTAA-3' (where N is any one of the four bases A, T, C, and G);
[0043] Forward primer: 5′-FAM-GGAGGCTCTCGGGACGAC-3′;
[0044] Reverse primer: 5′-Biotin-TTACGATTGCAGCATCGGGACG-3′;
[0045] Capture strand cDNA: 5′-GTCGTCCCGAGAGCCATA-BioTEG-3′.
[0046] (2) Screening nucleic acid aptamers of maytansine using Capture-SELEX technology.
[0047] 2.1. Hybridization of library and capture chain: After the initial library or secondary library is dissolved and quantified, the hybridization ratio of library to capture chain (1:5) is optimized. In the first round of screening, 1 nmol of random single-stranded DNA library and 5 nmol of capture chain cDNA are dissolved in 250 μL of screening buffer (the components of screening buffer are: 1.8 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl and 2 mM MgCl2, pH 7.4), mixed and then divided into 5 tubes, 50 μL per tube, and slowly annealed and hybridized in a PCR instrument, the annealing and hybridization program is: 95℃10min; 60℃10min; 25℃30min; the secondary library and capture chain of the remaining rounds of screening are annealed and hybridized in a PCR instrument according to the above hybridization ratio.
[0048] 2.2. Filling of Streptavidin Agarose Beads: The centrifugal micro-chromatography column was sterilized by ultraviolet light before use. After that, 600 μL of 250 nM irrelevant sequence (Random, 5'-GCGGAGCGTGGCAGG-3') was added to the treated column and incubated on a test tube rotator for 10 min at room temperature to block the nonspecific adsorption sites in the centrifugal micro-chromatography column. After blocking, the centrifugal micro-chromatography column was washed with 600 μL of washing buffer (the composition of the washing buffer was: 3.8 mM NaH2PO4, 16.2 mM Na2HPO4 and 150 mM NaCl, pH 7.5), and washed three times to remove the residual irrelevant sequence. Then, 250 μL of streptavidin agarose beads were added to the centrifugal micro-chromatography column, and the protective solution was removed after centrifugation at 1000×g for 30 s. The beads were washed three times with 250 μL of washing buffer (the composition of the washing buffer was the same as above) and four times with 250 μL of screening buffer.
[0049] 2.3. Fixation of the library: After filling the streptavidin agarose beads, add 250 μL of the library-capture chain hybrid complex to the centrifugal micro-chromatography column. Cover the end plug and the upper lid, place it on the test tube rotary mixer and incubate for 30 minutes (protected from light, room temperature), take it out and shake it manually every 2 minutes to ensure that the library is fully fixed. The fixation efficiency of the library can be calculated by the following formula: Fixation efficiency = (C1-C2) / C1×100% (Note: The concentration of the library-capture chain hybrid complex solution before incubation with streptavidin agarose beads is measured by a microplate spectrophotometer as C1; the concentration of the solution in the outer tube obtained by centrifugation after incubation of the library-capture chain hybrid complex solution with streptavidin agarose beads is C2).
[0050] 2.4. Background elution: After the library is fixed, the streptavidin agarose beads are washed with 250 μL of screening buffer each time to wash away the unbound and weakly bound library molecules. The number of washes is adjusted according to the screening pressure. The first round of screening is washed 10 times, and then adjusted in sequence, with each wash lasting about 2 minutes. The solutions after each wash are collected and named Wash#1, Wash#2, ..., Wash#final (final means the last wash of each round of screening).
[0051] 2.5. Negative screening: Negative screening starts from the 4th round of screening. During negative screening, add 250μL of screening buffer containing 2.5% DMSO to the centrifugal micro-chromatography column, and cover the plug at the end of the column and the lid at the top. Place it on a test tube rotary mixer and incubate for a certain period of time. The negative screening time is adjusted according to the screening pressure. After the negative screening is completed, remove the plug at the end, put the column in a 1.5mL outer tube, and collect the solution in the outer tube after centrifugation at 1000×g for 1min. Repeat the negative screening operation, collect the solutions after two negative screenings, and name them Counter#1 and Counter#2 respectively.
[0052] 2.6. Washing after negative screening: After negative screening is completed, an additional washing step is required before positive screening. The purpose is to fully wash away the polar organic solvent DMSO introduced by negative screening and the residual ssDNA dissociated during the negative screening process in the centrifugal micro-chromatography column. The number of washes after negative screening is adjusted in sequence according to the screening pressure. Add 250μL of screening buffer for each wash and gently blow the solution with a gun tip. After blowing for about 2 minutes, centrifuge at 1000×g for 1 minute, collect the solution after each wash, and name them W#1, W#2, ..., W#final (final means the last wash of each round of screening).
[0053] 2.7. Positive screening: During positive screening, add 250 μL of target maytansine (dissolved in 2.5% DMSO) to the centrifugal micro-chromatography column, cover the plug at the end of the column and the lid at the top, and incubate on a test tube rotary mixer for a certain period of time. The incubation time of the positive screening and the concentration of the added target are adjusted according to the screening pressure. After the incubation is completed, put the column in a 1.5mL outer tube, and collect the solution in the outer tube after centrifugation at 1000×g for 1min. Repeat the positive screening operation, collect the solutions after two positive screenings, and name them Target#1 and Target#2 respectively.
[0054] 2.8. PCR amplification: Combine the products of the two positive screenings in 2.7, take 100 μL of the positive screening products collected in 2.7 for PCR amplification to obtain PCR double-stranded products. The PCR amplification conditions are: 94℃ pre-denaturation for 5min; 94℃ denaturation for 30s, 62.7℃ annealing for 30s, 72℃ extension for 30s, after a suitable number of cycles (optimized according to 3% agarose electrophoresis); final extension at 72℃ for 4min. After the PCR is completed, collect all PCR double-stranded products and merge them into an EP tube.
[0055] 2.9. Preparation of single-stranded DNA: Take 150μL of streptavidin agarose beads in a 1.5mL low-adsorption EP tube, centrifuge at 1000×g for 30s, and discard the supernatant protection solution. Then add 400μL of washing buffer to wash the beads. During the washing process, gently blow the beads with the tip of the gun. After sufficient blowing, centrifuge to remove the washing solution. Wash three times in total. Add the combined PCR product to the above-pretreated beads, incubate at room temperature and light-proof conditions for 30 minutes, and mix 6-10 times during incubation to ensure that the biotinylated PCR product can be fully fixed on the streptavidin agarose beads. After incubation, centrifuge the sample at 1000×g for 30s and discard the supernatant. Add 200μL of washing buffer to wash, wash 5 times in total, wash away excess enzymes, primers and double-stranded DNA that is not fully fixed. At the same time, because the PCR buffer contains Mg 2+ , multiple use without Mg 2+ Washing with washing buffer can fully realize solvent exchange and avoid the generation of Mg(OH)2 precipitation caused by the addition of NaOH solution in subsequent operations. After washing, add 300μL of DNA denaturation solution (200mM NaOH solution) to the microbeads, incubate for 15min under alkaline hydrolysis in the dark, then centrifuge at 1000×g for 30s, and collect the supernatant; then take 80μL, 70μL, and 50μL of DNA denaturation solution to perform the same alkaline hydrolysis treatment on the above microbeads, centrifuge and collect the supernatant three times after alkaline hydrolysis; combine the 4 supernatants to obtain a single-stranded DNA library containing about 500μL, which is placed in a 1.5mL EP tube.
[0056] 2.10. Desalting and concentration of single-stranded DNA: The large amount of NaOH introduced during alkaline hydrolysis not only changes the pH of the screening buffer system but also changes the ionic strength of the screening buffer. Therefore, the prepared single-stranded DNA cannot be directly used in the next round of screening. Desalting treatment is required to remove the large amount of NaOH introduced during alkaline hydrolysis. + and OH -The desalting operation is as follows: first, hang the desalting column vertically on the bracket, open the top and bottom covers of the desalting column, and let the liquid in the desalting column flow out naturally by gravity; second, add at least 10mL of sterile water to the desalting column (1mL each time, at least 10 times), the purpose is to drive away the gas remaining in the desalting column gel, so that the solvent can flow more evenly and uniformly to ensure the separation effect; then, add the above-obtained 500μL single-stranded DNA library to the desalting column, and discard the naturally flowing liquid; finally, wait for the liquid to drip completely by gravity, and then add 1mL of freshly prepared sterile water to the desalting column. At this time, collect the flowing liquid, which is the desalted single-stranded DNA. After desalting, the obtained single-stranded DNA library is vacuum dried at 75℃ using a vacuum concentrating centrifugal dryer. After drying for about 2.5h, a single-stranded DNA powder (light yellow) is obtained, which is sealed and placed in a -20℃ refrigerator for storage and used as the next round of screening library.
[0057] 2.11. Screening cycle: First, centrifuge the dried single-stranded DNA powder to avoid powder splashing when opening the lid, which may cause loss of the library; second, add an appropriate amount of screening buffer to the powder to fully dissolve it; finally, use a UV spectrophotometer to measure the absorbance of the single-stranded DNA solution at 260nm, and calculate the amount of single-stranded DNA for the next round of screening based on the absorbance value. Repeat operations 2.1-2.10 until the screened library is fully enriched. In this process, different screening pressures are controlled in different screening rounds to increase the specificity and affinity of the screening sequence. After enrichment is completed, the screening process ends.
[0058] 2.12. Monitoring of the screening process: The screening process was monitored simultaneously by fluorescence and electrophoresis. Principle of fluorescence monitoring: During the screening process, the 5' end of the forward primer was modified with the fluorescent dye FAM. After PCR amplification and alkaline hydrolysis to prepare the secondary library, starting from the second round of screening, the 5' end of the DNA library was modified with FAM. Therefore, the amount of ssDNA eluted in each round of screening can be determined by detecting the fluorescence value of the fluorescent dye FAM.
[0059] The principle of electrophoresis monitoring: the volume of background elution, negative screening volume, volume of solution washing after negative screening, and positive screening volume in each round of screening are all 250μL. Collect the solution after each step of operation and make corresponding marks, and then take 5μL from the collected solution to prepare a PCR amplification system with a total volume of 50μL. The specific reaction system is: 25μL 2×PCR Mix, 2.5μL FAM-forward primer (10μM), 2.5μL Biotin-reverse primer (10μM), 5μL template DNA, 15μL sterile water. The reaction amplification conditions are: 94℃ pre-denaturation for 5min; 94℃ denaturation for 30s, 62.7℃ annealing for 30s, 72℃ extension for 30s, amplification for 10 cycles; final extension at 72℃ for 4min. After the PCR is completed, 3% agarose gel electrophoresis and imaging analysis are performed, and the brightness of the electrophoresis band corresponds to the amount of ssDNA eluted in each step. Therefore, under the same PCR reaction system and amplification times, the brightness of the electrophoresis bands of the PCR products will be different due to different template concentrations, and the screening process can be monitored based on the brightness of the bands.
[0060] According to the results of the screening process monitoring, the enriched library was sequenced and optimized, and finally the nucleic acid aptamer Seq2-X that can be used to specifically recognize maytansine was obtained. The 5' end of the nucleic acid aptamer Seq2-X was labeled with FAM, which was recorded as the nucleic acid aptamer FAM-Seq2-X, and its DNA fragment was:
[0061] 5'-FAM-CTCTCGGGACGACTTGTCATGTGTAGAAGGAGTGGGTTGAGATGTCGTCCC-3'.
[0062] In the present invention, the nucleotide sequence of the nucleic acid aptamer Seq2-X is combined with biotin, digoxigenin, fluorescent substances, nanoluminescent materials or enzyme labels, which can achieve the same or similar technical effects as Example 1. In this embodiment, the fluorescent substance is a FAM fluorescent group, but other fluorescent groups can also produce the same technical effects, such as: Cy5 fluorescent group.
[0063] The nano-luminescent material can be quantum dots or up-conversion nanoparticles. The enzyme label can be horseradish peroxidase or sucrase.
[0064] In the present invention, under the premise that the overall structure of Seq2-X remains unchanged, a nucleic acid aptamer that is phosphorylated, methylated, aminated, thiolated or isotopized at a certain position on the nucleotide sequence of the nucleic acid aptamer Seq2-X can achieve the same or similar technical effects as Example 1. Amination is to label the 5' or 3' end of the nucleic acid aptamer Seq2-X nucleotide sequence with an amino group -NH2; thiolation is to label the 5' or 3' end of the nucleic acid aptamer Seq2-X nucleotide sequence with a thiol group -SH.
[0065] In the present invention, the nucleic acid aptamer whose DNA sequence is any one of the following four sequences can achieve the same or similar technical effects as those in Example 1:
[0066] (1) having a nucleotide sequence homology of more than 60% with the nucleic acid aptamer Seq2-X;
[0067] (2) a sequence that hybridizes with the nucleotide sequence of the nucleic acid aptamer Seq2-X;
[0068] (3) an RNA sequence transcribed from the nucleotide sequence of the nucleic acid aptamer Seq2-X;
[0069] (4) It is a derivative of Seq2-X, wherein the derivative is a phosphorothioate backbone derived from the backbone of the nucleotide sequence of the nucleic acid aptamer Seq2-X, or is a corresponding locked nucleic acid or peptide nucleic acid modified from the nucleic acid aptamer.
[0070] Comparative Example 1
[0071] The nucleotide sequence of the control chain is: Control: 5'-ATTGCGAAACGGAAGTCGCTTCTACACTTCCGATTCGCAAT-3'.
[0072] Experiment 1: Use the Mfold service to simulate the secondary structure of the nucleic acid aptamer sequence in Example 1.
[0073] The schematic diagram of the structure after the secondary structure simulation of the nucleic acid aptamer sequence of Example 1 using the Mfold service is shown in Figure 1 :from Figure 1 It can be seen that the Seq2-X sequence structure mainly includes a large loop, a small loop and two stem regions.
[0074] Experiment 2: Use a multifunctional microplate reader to investigate the optimal concentration ratio of the nucleic acid aptamer FAM-Seq2-X and the quenching probe Quencher.
[0075] Draw a fluorescence quenching saturation curve to determine the dissociation constant K when the complementary hybridization reaches equilibrium. d1, where the horizontal axis is a series of different concentrations of quenching probes (the nucleotide sequence of the quenching probe Quencher is: 5'-GTCGTCCCGAGAG-BHQ-1-3'), and the vertical axis is the fluorescence intensity. The specific process is: FAM-Seq2-X and quenching probe Quencher synthesized by Sangon Biotechnology (Shanghai) Co., Ltd. are centrifuged at 10000r for 5 minutes, and a certain volume of screening buffer is added to prepare a solution with a concentration of 10μM for standby use. FAM-Seq2-X with a final concentration of 50nM is mixed with a series of quenching probes Quencher with different final concentrations (0μM, 41μM, 66μM, 83μM, 124μM, 166μM, 415μM, 830μM) and added to the screening buffer, and the above solution is slowly annealed and hybridized in a PCR instrument (the hybridization procedure is the same as above). Then, a fluorescence test was performed using a multifunctional microplate reader (operated in a dark environment), and the test conditions were: Ex = 488nm, Em = 520nm, Ex Slit = 10.0nm, Em Slit = 10.0nm. The fluorescence quenching saturation curve of the hybridization of the nucleic acid aptamer and the quenching probe was drawn to determine the dissociation constant K when the complementary hybridization of the two reached equilibrium. d 1. Three parallel samples were set up for each concentration in the experiment.
[0076] Figure 2 This is the concentration optimization diagram of the incubation of nucleic acid aptamer FAM-Seq2-X and quencher probe Quencher, where the horizontal axis is a series of quencher probes with different concentrations, and the vertical axis is the fluorescence intensity. It can be seen from the figure that when the concentration of nucleic acid aptamer FAM-Seq2-X is fixed at 50nM, as the concentration of the quencher probe continues to increase, the fluorescence intensity of the system gradually decreases and then remains unchanged. When the concentration of the quencher probe is about 28.2nM, the fluorescence of FAM-Seq2-X is quenched by half, according to the following formula: The calculated K d 1 is approximately 3.2nM.
[0077] Experiment 3: Use a multifunctional microplate reader to examine the fluorescence recovery saturation curve after incubation with different concentrations of maytansine at the optimal quenching ratio of FAM-Seq2-X and Quencher.
[0078] Draw a fluorescence recovery saturation curve to determine the dissociation constant K when the target-induced aptamer-quenching probe complex dissociates to reach equilibrium d2, where the abscissa is the target maytansine with gradually increasing concentrations, and the ordinate is the fluorescence intensity. The specific process is: under the optimal quenching ratio of nucleic acid aptamer to quenching probe (50nM﹕250nM), a series of concentrations of target maytansine (the target final concentrations are 0μM, 0.1μM, 0.5μM, 1μM, 2μM, 3μM, 5μM, 7.5μM, 10μM, 20μM, 50μM and 100μΜ) are added to the nucleic acid aptamer-quenching probe complex solution, and incubated in an oscillating thermostatic metal bath at 25°C and protected from light for 1h. Three parallel samples are set for each concentration in the experiment. Subsequently, a fluorescence test is performed using a multifunctional microplate reader (operated in a dark environment), and the test conditions are: Ex=488nm, Em=520nm, Ex Slit=10.0nm, Em Slit=10.0nm. Then, the fluorescence recovery saturation curve of the target binding to the aptamer-quencher probe complex sensor was plotted to determine the dissociation constant K when the target induced the aptamer-quencher probe complex to dissociate and reach equilibrium. d 2.
[0079] Figure 3 The fluorescence recovery saturation curves after adding different concentrations of maytansine to incubate at the optimal quenching ratio of FAM-Seq2-X to Quencher in Example 1 of the present invention are shown in FIG. 1 , wherein the abscissa represents the target maytansine with gradually increasing concentrations, and the ordinate represents the fluorescence intensity. Figure 3 It can be seen from the results that: with the continuous increase of maytansine concentration, the fluorescence intensity of the system gradually recovered and remained basically unchanged. When the maytansine concentration was about 1.8μM, the quenched fluorescence was restored by half. According to the following formula: The calculated K d 2 is approximately 0.13.
[0080] K d 1 and K d 2. Compare the equilibrium dissociation constant K of the binding of maytansine and nucleic acid aptamer d (K d =K d 1 / K d 2), the equilibrium dissociation constant K obtained from this d As shown in Table 1 below.
[0081] Table 1 Equilibrium dissociation constant results
[0082] sequence name <![CDATA[K d (nM)]]> Seq2-X 24.6
[0083] Figure 3 and equilibrium dissociation constant K d The calculation results show that the nucleic acid aptamer Seq2-X of this embodiment has a strong binding ability to maytansine, and the equilibrium dissociation constant is at the nanomolar level.
[0084] Experiment 4: Strand displacement fluorescence method was used to investigate the specificity of FAM-Seq2-X.
[0085] Take 15 μL of 10 μM FAM-Seq2-X and 75 μL of 10 μM quencher probe (the nucleotide sequence of the quencher probe Quencher is: 5'-GTCGTCCCGAGAG-BHQ-1-3') and dissolve them in a total volume of 3000 μL of screening buffer. After fully mixing, divide them into 9 groups, 100 μL of each sample, and prepare three copies in parallel. Then, add 100 μL of blank sample (screening buffer containing 2.5% DMSO), 100 μL of 3 μM target maytansine and 100 μL of 100 μM other 7 small molecule compounds (cisplatin, 5-fluorouracil, tamoxifen, (S)-10-hydroxycamptothecin, docetaxel, carbaryl, thiamethoxam) to these 9 groups of samples. After adding the samples, incubate these 9 groups of samples in a shaking thermostatic metal bath at 25°C and in the dark for 1 hour. After incubation, the fluorescence intensity of the solution was measured using a multifunctional microplate reader (Ex=488 nm, Em=520 nm, Ex Slit=10.0 nm, Em Slit=10.0 nm).
[0086] Figure 4 This is the investigation result of the specificity of the nucleic acid aptamer FAM-Seq2-X in Example 1 of the present invention. Figure 4 The detection results show that the nucleic acid aptamer FAM-Seq2-X of this example can specifically recognize maytansine, but not other small molecule compounds.
[0087] Example 2
[0088] An application of the nucleic acid aptamer Seq2-X of Example 1 in improving the solubility of maytansine.
[0089] The specific application method includes the following steps:
[0090] (1) Weigh an excess amount of maytansine powder and dissolve it in the screening buffer. Ultrasonicate at 100 W for 1 h to prepare a saturated maytansine suspension.
[0091] (2) Denature the nucleic acid aptamer Seq2-X at 95°C for 5 min and keep it on ice at 4°C for more than 10 min for later use.
[0092] (3) The aptamer was added to the maytansine suspension to make the final concentration of DNA in the solution 3 μM. The solution was thoroughly mixed and incubated in a shaking thermostatic metal bath at 25° C. for 0, 1, 2, 4, 6, 8, 12, and 24 h.
[0093] (4) After incubation, all samples were centrifuged in a desktop low-temperature refrigerated centrifuge at 10,000 × g for 10 min and the supernatant was collected. The ultraviolet absorption of the sample supernatant from 500 nm to 200 nm was measured using an ultraviolet spectrophotometer, and the absorbance values at 233 nm and 260 nm were recorded. Each sample was prepared in triplicate.
[0094] Experiment 5: Investigate the effect of different incubation times of maytansine and nucleic acid aptamers on improving the solubility of maytansine.
[0095] Since the solubility of maytansine is poor, it takes a long time to reach dissolution equilibrium. Therefore, we first optimize the incubation time of maytansine and nucleic acid aptamers. According to the method of Example 2, the absorbance values of maytansine at 233nm and 260nm were recorded respectively under different incubation times. According to the following equations, the solubility (C x ).
[0096] A 233 =2.98×10 4 C x +1.77×10 5 C y
[0097] A 260 =1.50×10 4 C x +3.67×10 5 Cy
[0098] Figure 5 The results of nucleic acid aptamer Seq2-X improving the solubility of maytansine at different incubation times. Figure 5 The results showed that when the incubation time of the aptamer Seq2-X with a final concentration of 3 μM and maytansine was extended from 1 h to 2 h, the solubility of maytansine was significantly improved, but as the incubation time continued to increase, the solubility of maytansine did not increase further and basically reached saturation. Considering that the dissolution equilibrium of maytansine is a dynamic process, it takes a long time to reach equilibrium. Therefore, in subsequent experiments, we directly incubated maytansine and the aptamer in an oscillating thermostatic metal bath at 25°C overnight for 24 h.
[0099] Experiment 6: Investigate the effect of different concentrations of nucleic acid aptamers on improving the solubility of maytansine.
[0100] The method of Example 2 was used to examine the effect of gradient concentrations of nucleic acid aptamers (0 μM, 0.5 μM, 1 μM, 2 μM, 5 μM, 10 μM, 20 μM) on improving the solubility of maytansine.
[0101] Figure 6The results of different concentrations of aptamer Seq2-X to improve the solubility of maytansine. The results in the figure show that: under the incubation time of 24h, as the concentration of the aptamer increases from 0.5μM to 20μM, the solubility of maytansine gradually increases. When the concentration of the aptamer reaches 10μM, the solubilization ability of the hydrophilic aptamer approaches a plateau. When the concentration of the aptamer continues to increase to 20μM, the solubility of maytansine increases from the initial 17μM to 61μM.
[0102] Example 3
[0103] An application of the nucleic acid aptamer Seq2-X of Example 1 in broadening the therapeutic window of maytansine.
[0104] The specific application method is:
[0105] (1) Maytansine was dissolved in a screening buffer containing 0.5% DMSO, and then sonicated for later use.
[0106] (2) Denature the aptamer Seq2-X and the control chain Control at 95°C for 5 min and keep them on ice at 4°C for more than 10 min for later use.
[0107] (3) Using human tongue squamous cell carcinoma resistant cells Tca8113 / BLM as a model, when the concentration of maytansine was 400 nM, gradient concentrations of nucleic acid aptamer Seq2-X (0 nM, 10 nM, 100 nM, 200 nM, 400 nM, 1000 nM, 2000 nM, 5000 nM) were added to the above 400 nM maytansine solution to form a series of complexes with different concentrations, and the killing effect of the complex on Tca8113 / BLM cells was investigated.
[0108] (4) When the administration concentration of maytansine was 1000 nM, gradient concentrations of nucleic acid aptamer Seq2-X (0 nM, 10 nM, 100 nM, 200 nM, 400 nM, 1000 nM, 2000 nM, 5000 nM) were added to the above 1000 nM maytansine solution to form a series of complexes with different concentrations, and the killing effect of the complex on Tca8113 / BLM cells was investigated.
[0109] (5) When the administration concentration of maytansine was 2000 nM, gradient concentrations of nucleic acid aptamer Seq2-X (0 nM, 10 nM, 100 nM, 200 nM, 400 nM, 1000 nM, 2000 nM, 5000 nM) were added to the above 2000 nM maytansine solution to form a series of complexes with different concentrations, and the killing effect of the complex on Tca8113 / BLM cells was investigated.
[0110] (6) The control chain was processed in the same way as steps 3-5 above.
[0111] Experiment 7: Investigate the effect of nucleic acid aptamer Seq2-X in broadening the therapeutic window of maytansine.
[0112] The specific experimental process is: draw the inhibition curve of maytansine alone on human tongue squamous cell carcinoma resistant cells Tca8113 / BLM, determine the optimal drug incubation time and the drug half inhibitory concentration IC 50 , select the IC 50 Three drug concentrations (400nM, 1000nM, 2000nM) with obvious changes in the slope of the curve near the value were investigated respectively. When the drug concentration was fixed, the effect of the nucleic acid aptamer Seq2-X on the cytotoxicity of maytansine was investigated when the addition of Seq2-X changed from insufficient to excessive. The probe Control was selected as the control chain, and 5 copies of each group of samples were prepared in parallel.
[0113] Figure 7 Investigation results of the nucleic acid aptamer Seq2-X to broaden the therapeutic window of maytansine. Figure 7 The results of the investigation show that when the concentration of maytansine is 400nM, 1000nM and 2000nM respectively, as the concentration of the added aptamer gradually increases (from 0nM to 5000nM), the killing effect of the aptamer-maytansine complex on drug-resistant cells becomes more and more obvious. However, the addition of the control chain to form a control chain-maytansine complex of different concentrations does not change the efficacy of maytansine. It shows that the aptamer increases the content of maytansine drug entering the cell and can significantly increase the cytotoxicity of low-concentration drugs. The aptamer-maytansine complex formed at the same time may also affect the process of drug-resistant cells pumping out drugs. In summary, aptamers can enhance the efficacy of maytansine, overcome the drug resistance of tumor cells to a certain extent, and ultimately broaden the therapeutic window of maytansine.
[0114] Example 4
[0115] An application of the nucleic acid aptamer Seq2-X of Example 1 in improving the stability of maytansine.
[0116] The specific application method is:
[0117] (1) Maytansine was dissolved in a screening buffer containing 0.5% DMSO, and then sonicated for later use.
[0118] (2) Denature the nucleic acid aptamer Seq2-X at 95°C for 5 min and keep it on ice at 4°C for more than 10 min for later use.
[0119] (3) Using MCF-7 cells as a model, four groups of samples, namely 2 nM maytansine, 2 nM maytansine + 1 nM Seq2-X, 2 nM maytansine + 2 nM Seq2-X, and 2 nM maytansine + 100 nM Seq2-X, were placed at room temperature in the dark for 1 day, 4 days, and 7 days, respectively, and then added to the above cells for incubation for 72 hours after preparation, and the cell survival rate was then measured.
[0120] (4) Using SCC4 cells as a model, four groups of samples, namely, 132 nM maytansine, 132 nM maytansine + 10 nM Seq2-X, 132 nM maytansine + 132 nM Seq2-X, and 132 nM maytansine + 1000 nM Seq2-X, were placed at room temperature in the dark for 1 day, 4 days, 7 days, and then added to the above cells for incubation for 72 h after being prepared. The cell survival rate was then measured.
[0121] (5) Using Tca8113 / BLM cells as a model, four groups of samples, namely 1000nM maytansine, 1000nM maytansine + 100nMSeq2-X, 1000nM maytansine + 1000nM Seq2-X, and 1000nM maytansine + 2000nM Seq2-X, were placed at room temperature in the dark for 1 day, 4 days, 7 days, and then added to the above cells for incubation for 72 hours after preparation, and the cell survival rate was measured.
[0122] Experiment 8: The effect of nucleic acid aptamer Seq2-X in improving the stability of maytansine.
[0123] Three different cell lines (MCF-7, SCC4, and Tca8113 / BLM) were used as models and the IC obtained from the inhibition curve fitting was selected. 50 The concentration near the value is investigated. Specific experimental method:
[0124] (1) Experimental method using MCF-7 cells as a model:
[0125] First, prepare four groups of samples:
[0126] Group 1 (free maytansine): 2 nM maytansine.
[0127] The second group (maytansine-deficient nucleic acid aptamer): 2nM maytansine+1nM Seq2-X.
[0128] The third group (Maytansine-equal ratio of nucleic acid aptamers): 2nM Maytansine + 2nM Seq2-X.
[0129] The fourth group (Maytansine-excess nucleic acid aptamer): 2nM Maytansine + 100nM Seq2-X.
[0130] The samples were placed at room temperature and protected from light for 0 days (prepared and used immediately), 1 day, 4 days, and 7 days, and the four groups of samples were recorded as Day 0, Day 1, Day 4, and Day 7. Then, the four groups of samples stored in vitro for different days were added to the cells and incubated for 72 hours. After the incubation, the cell survival rate was measured.
[0131] (2) Experimental methods using SCC4 cells as a model:
[0132] First, prepare four groups of samples:
[0133] Group 1 (free maytansine): 132 nM maytansine.
[0134] The second group (maytansine-deficient nucleic acid aptamer): 132nM maytansine+10nM Seq2-X.
[0135] The third group (Maytansine-equal ratio of nucleic acid aptamers): 132nM Maytansine + 132nM Seq2-X.
[0136] The fourth group (Maytansine-excess nucleic acid aptamer): 132nM Maytansine + 1000nM Seq2-X.
[0137] The samples were placed at room temperature and protected from light for 0 days (prepared and used immediately), 1 day, 4 days, and 7 days, and the four groups of samples were recorded as Day 0, Day 1, Day 4, and Day 7. Then, the four groups of samples stored in vitro for different days were added to the cells and incubated for 72 hours. After the incubation, the cell survival rate was measured.
[0138] (3) Experimental methods using Tca8113 / BLM cells as a model:
[0139] First, prepare four groups of samples:
[0140] Group 1 (free maytansine): 1000 nM maytansine.
[0141] The second group (maytansine-deficient nucleic acid aptamer): 1000 nM maytansine + 100 nM Seq2-X.
[0142] The third group (Maytansine-equal ratio of nucleic acid aptamers): 1000nM Maytansine+1000nM Seq2-X.
[0143] The fourth group (Maytansine-excess nucleic acid aptamer): 1000nM Maytansine + 2000nM Seq2-X.
[0144] The samples were placed at room temperature and protected from light for 0 days (prepared and used immediately), 1 day, 4 days, and 7 days, and the four groups of samples were recorded as Day 0, Day 1, Day 4, and Day 7. Then, the four groups of samples stored in vitro for different days were added to the cells and incubated for 72 hours. After the incubation, the cell survival rate was measured.
[0145] Figure 8 The results of the investigation of the nucleic acid aptamer Seq2-X to improve the stability of maytansine. The results of the investigation show that after 1 day, 4 days and 7 days of storage, the drug efficacy of free maytansine is lower than that of freshly prepared maytansine. The drug that has been stored for 7 days has a weak killing effect on the three cells of MCF-7, SCC4 and Tca8113 / BLM, indicating that the efficacy of free maytansine is significantly reduced after being stored in vitro for more than 4 days. However, the maytansine-nucleic acid aptamer complex still has a killing effect on these three cells after 7 days of storage in vitro, indicating that nucleic acid aptamers can improve the stability of drugs.
[0146] The above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as above in the preferred embodiment, it is not used to limit the present invention. Any technician familiar with the art can make many possible changes and modifications to the technical solution of the present invention by using the methods and technical contents disclosed above without departing from the spirit and technical solution of the present invention, or modify it into an equivalent embodiment of equivalent changes. Therefore, any simple modification, equivalent replacement, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention, still fall within the scope of protection of the technical solution of the present invention.
Claims
1. A nucleic acid aptamer of maytansine, characterized in that: The nucleic acid aptamer is Seq2-X, and the DNA sequence of Seq2-X is shown in SEQ ID NO.
1.
2. The nucleic acid aptamer according to claim 1, characterized in that The nucleic acid aptamer is a nucleic acid aptamer that is combined with biotin, digoxigenin, a fluorescent substance, a nanoluminescent material or an enzyme label on the DNA sequence of Seq2-X.
3. The nucleic acid aptamer according to claim 2, characterized in that The fluorescent substance is a FAM fluorescent group or a Cy5 fluorescent group; the nano luminescent material is a quantum dot or an up-conversion nano particle; and the enzyme marker is horseradish peroxidase or sucrase.
4. The nucleic acid aptamer according to claim 1, characterized in that The nucleic acid aptamer is phosphorylated, methylated, aminated, thiolated or isotopized at a certain position on the nucleotide sequence of the nucleic acid aptamer Seq2-X under the premise that the overall structure of Seq2-X remains unchanged.
5. The nucleic acid aptamer according to claim 4, characterized in that The amination is to label the 5' or 3' end of the nucleotide sequence of the nucleic acid aptamer Seq2-X with an amino group -NH2; the thiolation is to label the 5' or 3' end of the nucleotide sequence of the nucleic acid aptamer Seq2-X with a thiol group -SH.
6. The nucleic acid aptamer according to any one of claims 1 to 5, characterized in that The nucleic acid aptamer is a nucleic acid aptamer whose DNA sequence is any one of the following four sequences: (1) having a nucleotide sequence homology of more than 60% with the nucleic acid aptamer Seq2-X; (2) a sequence that hybridizes with the nucleotide sequence of the nucleic acid aptamer Seq2-X; (3) an RNA sequence transcribed from the nucleotide sequence of the nucleic acid aptamer Seq2-X; (4) It is a derivative of Seq2-X, wherein the derivative is a phosphorothioate backbone derived from the backbone of the nucleotide sequence of the nucleic acid aptamer Seq2-X, or is a corresponding locked nucleic acid or peptide nucleic acid modified from the nucleic acid aptamer according to any one of claims 1 to 5.
7. Use of the nucleic acid aptamer according to any one of claims 1 to 6 for improving the solubility of maytansine.
8. Use of the nucleic acid aptamer according to any one of claims 1 to 6 in broadening the therapeutic window of maytansine.
9. Use of the nucleic acid aptamer according to any one of claims 1 to 6 in improving the stability of maytansine.
10. Use of the nucleic acid aptamer according to any one of claims 1 to 6 in a drug carrier.
Citation Information
Patent Citations
Nucleic acid aptamer and detection kit for detecting human drug-resistant hepatoma cell strain HepG2 / ADM
CN110564731A
Aptamer derivative, aminated aptamer derivative, applications of aptamer derivative and aminated aptamer derivative, and drug conjugate
CN110760516A
Aptamer of methotrexate, aptamer derivative and application of aptamer and aptamer derivative
CN113249386A
Cited By
Method for determining affinity by using micro-fluidic chip, micro-fluidic chip and nucleic acid aptamer
CN120629554A
Method for determining affinity using microfluidic chip, microfluidic chip and aptamer
CN120629554B
